Previous Summit

align="left">In 2010, much emphasis has been placed on helping Europe climb back to the top of the R&D ladder. The European pharmaceutical sector must currently focus on innovative solutions which can integrate seamlessly with existing technologies and strategies, which are key factors in bringing drugs to market quicker and more effectively. Given the multitude of new pharmaceuctical R&D institutes and the determination of the EU to revive Europe's status as an innovation leader in drug discovery, returns on such R&D investment over the next few years could potentially boom. Leaders in the R&D space know that now is the time to commit to drug discovery.

"This meeting provided an excellent opportunity to meet key thinkers in the clinical study Pharma space and to present the contributions of our technology to them."

Scott Watson, Aperio

Who was there...

Partners

Delegate

Michael Richter

Michael Richter
Global Clinical Trial Coordinator
F. Hoffmann-La Roche

www.roche.com

Nicholas Dracopoli

Nicholas Dracopoli
VP Biomarkers and Translational Research
Johnson & Johnson

www.jnj.com

Michael Herschel

Michael Herschel
Director of Clinical Research
GSK

www.gsk.com

Melinda Bickerstaff

Melinda Bickerstaff
VP Knowledge Management
Bristol-Myers Squibb

www.bms.com

Martin Elminger

Martin Elminger
Director Biomarkers
Nycomed

www.nycomed.com

Beate Schaper

Beate Schaper
Head of Labelling and Information Officer
Wyeth

www.wyeth.com

Lolke de Haan

Lolke de Haan
Head of Toxicology, Biologics Safety Assessment
MedImmune

www.MedImmune.com

View all